Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
Maria Isabel Del Olmo-GarcíaDavid Hervás MarínJana Caudet EstebanAntonio Ballesteros Martin-PortuguésAlba Cerveró RubioMiguel Angel Arnau VivesAna Catalá GregoriMaite Penalba MartínezJuan Francisco Merino-TorresPublished in: The Journal of international medical research (2021)
Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of hypoglycemia. These results support the need to explore liraglutide in a larger multicenter trial. Trial registration: The study was approved by the National Medical Ethics Committee of Spain. The study was registered at European Clinical Trials Database (EudraCT): 2014003298-40.
Keyphrases
- acute coronary syndrome
- clinical trial
- type diabetes
- end stage renal disease
- phase ii
- healthcare
- phase iii
- study protocol
- public health
- ejection fraction
- chronic kidney disease
- percutaneous coronary intervention
- antiplatelet therapy
- newly diagnosed
- risk factors
- metabolic syndrome
- quality improvement
- coronary artery disease
- deep learning
- open label
- big data
- skeletal muscle